iBio, Inc.

IBIO Healthcare Biotechnology

iBio, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $100,000.00, down 75.0% from fiscal 2025.

Revenue
+100.0%
EPS
+80.5%
Free cash flow
−35.3%

Quarter to June 2026, against a year earlier

0.75 0.02 +2.74%
Market cap
$44.4M
P/E
0.0×
Fwd P/E
−2.0×
Dividend yield
—
F-score
4/9
Altman Z
2.80
Beneish M
33.49
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Jun '17 Jun '18 Jun '19 Jun '20 Jun '21 Jun '22 Jun '23 Jun '24 Jun '25 Jun '26
Total current assets
8.57 16.29 4.81 61.75 104.60 45.07 26.26 15.67 9.72 92.22
Total non-current assets
27.44 26.80 25.78 32.44 42.37 54.34 14.95 13.06 13.46 6.89
Total Assets
36.01 43.08 30.59 94.19 146.97 99.41 41.21 28.73 23.19 99.11
Total current liabilities
2.01 2.04 3.46 5.24 6.65 30.44 22.11 3.84 6.11 11.75
Total non-current liabilities
25.08 24.88 24.67 32.35 31.76 5.49 3.72 3.57 2.20 1.65
Total liabilities
27.10 26.92 28.13 37.58 38.40 35.92 25.83 7.41 8.31 13.40
Common Equity (Total)
8.92 16.16 2.46 56.61 108.57 63.49 15.38 21.32 14.88 85.71
Shareholders Equity (Total)
8.92 16.16 2.46 56.61 108.57 63.49 15.38 21.32 14.88 85.71
Total Debt
25.27 25.08 24.88 32.91 32.72 25.68 13.69 1.28 0.83 —

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 26 Oct 2026